AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal ...

Wainzua's potential approval by the European Commission would make it the only self-administered, monthly treatment via an auto-injector for ATTRv-PN in the EU. AstraZeneca and Ionis ...

AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

The EU antitrust regulators can either clear the deal with or ... The U.K. pharmaceutical company AstraZeneca has become the ...

AstraZeneca’s results were helped by resilient demand for its cancer and rare diseases medicines, after third-quarter results ...

(Sharecast News) - Pharma titan AstraZeneca has announced that its Wainzua nerve damage treatment has been recommended for approval in the EU. Wainzua, jointly developed with California biotech ...

Tezspire is currently approved for the treatment of severe asthma in the US, EU, Japan, and nearly 60 countries across the globe. It is approved as a single-use pre-filled syringe and auto-injector ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

The European Union's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca and Ionis Pharmaceuticals’ Wainzua (eplontersen) to treat hereditary ...